hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06323473 id: Maitake001 briefTitle: Maitake for Integrative Cancer Care acronym: Maitake overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2025-08-01 date: 2025-09-01 date: 2024-03-21 date: 2024-03-21 name: The Canadian College of Naturopathic Medicine class: OTHER briefSummary: Maitake is an edible mushroom that is used for both its nutritional and medicinal properties. Human and animal studies have shown Maitake may help improve immune function; however, its effectiveness in people with cancer is not clear. The investigators aim to measure if Maitake has any immunomodulatory effects when given alongside conventional systemic cancer therapy. conditions: Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Uncontrolled single arm clinical trial primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Black Maitake Prothera measure: Changes in absolute neutrophil count measure: Incidence of febrile neutropenia measure: Change in neutrophil to lymphocyte ratio (NLR) measure: Change in platelet to lymphocyte ratio (PLR) measure: Change in high-sensitivity C-reactive protein (CRP) measure: Changes in Quality of Life measure: Changes in hemoglobin A1c (HbA1c) measure: Incidence of adverse events measure: Incidence of dose reductions or delays in systemic therapy measure: Addition of new medications to combat neutropenia sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Centre for Health Innovation city: Ottawa state: Ontario zip: K2P 0M7 country: Canada name: Mark Legacy role: CONTACT phone: 613-792-1222 phoneExt: 1 email: mlegacy@thechi.ca lat: 45.41117 lon: -75.69812 facility: Canadian College of Naturopathic Medicine - Integrative Cancer Centre city: Toronto state: Ontario zip: M2K 1E2 country: Canada name: Daniel Lander role: CONTACT phone: 416-498-1255 phoneExt: 280 email: dlander@ccnm.edu lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06323460 id: OSU-23083 id: NCI-2024-00904 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) briefTitle: Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer overallStatus: RECRUITING date: 2024-04-01 date: 2025-12-31 date: 2025-12-31 date: 2024-03-21 date: 2024-03-21 name: Ohio State University Comprehensive Cancer Center class: OTHER briefSummary: This phase II trial studies how well using circulating tumor deoxyribonucleic acid (DNA) to guide lower dose radiation therapy works in treating patients with human papillomavirus infection (HPV)-associated oropharyngeal cancer. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Recently, a blood test has been developed to detect the human papillomavirus in the blood and determine how many viral particles are present. Researchers want to compare any good and bad effects of using the lower dose radiation therapy with chemotherapy compared to the usual standard of care dose chemotherapy in patients who clear the human papillomavirus particles from their blood. conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 conditions: Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 conditions: Oropharyngeal Squamous Cell Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 45 type: ESTIMATED name: Biospecimen Collection name: Carboplatin name: Cisplatin name: Computed Tomography name: External Beam Radiation Therapy name: Paclitaxel name: Positron Emission Tomography name: Questionnaire Administration measure: Positron emission tomography complete response measure: Progression free survival measure: Incidence of adverse events measure: Quality of life (QOL) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ohio State University Comprehensive Cancer Center status: RECRUITING city: Columbus state: Ohio zip: 43210 country: United States name: Sujith Baliga role: CONTACT phone: 614-293-5066 email: Sujith.baliga@osumc.edu name: Sujith Baliga role: PRINCIPAL_INVESTIGATOR lat: 39.96118 lon: -82.99879 hasResults: False
nctId: NCT06323447 id: PC002 briefTitle: Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia acronym: PC002 overallStatus: NOT_YET_RECRUITING date: 2024-06-30 date: 2025-04-30 date: 2025-05-28 date: 2024-03-21 date: 2024-03-21 name: Leuko Labs, Inc. class: INDUSTRY briefSummary: Pivotal study to validate the diagnostic performance of PointCheck, the first non invasive device to preliminary detect neutropenia in cancer patients receiving intermediate/high risk antineoplastic therapy. conditions: Diffuse Large B Cell Lymphoma conditions: Multiple Myeloma studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 210 type: ESTIMATED name: PointCheck measure: PointCheck Accuracy measure: PointCheck Precision measure: PointCheck Usability measure: PointCheck Errors measure: PointCheck Safety sex: ALL minimumAge: 10 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06323434 id: spice1 briefTitle: Spinal CSF Leaks in Chronic Subdural Hematoma acronym: SPICE overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2026-10 date: 2024-03-21 date: 2024-04-22 name: University of Freiburg class: OTHER briefSummary: Background: Chronic subdural hematoma (cSDH) is a type of intracranial bleeding, predominantly affecting the elderly and males, with an estimated incidence of 8/100.000. The collection of subdural fluid expands slowly, leading eventually to brain tissue compression that results in neurological impairment such as seizures, cognitive decline, and paresis. Most patients need neurosurgical evacuation of the blood to improve and to prevent further, possibly permanent deterioration. Evidently, the cause of such a bleeding must be investigated and if possible treated, or preventive strategies need to be installed if possible. Spinal cerebrospinal fluid (CSF) leaks are a known cause of cSDH but are widely underdiagnosed in this population.
The spinal CSF leak causes CSF loss that leads to intracranial hypotension, expansion of intracerebral veins, and traction to the brain and the surrounding tissues. A cSDH is a severe complication of such a leak and occurs in about 30% of all cases with a predominance among the elderly. It is crucial to identify these patients with a spinal leak as treatment pathways differ essentially from patients without a leak. Some smaller studies indicated a prevalence of spinal CSF leaks among cSDH patients of 30% to 80% depending on selection criteria (age, extend of cSDH). Notably, the entity of the CSF-venous fistula, that has been discovered as recent as 9 years ago, and that by now is accounting for 20-25% of all spinal leaks, has not been considered in previous research on cSDH and spinal CSF leaks.
nctId: NCT06323421 id: STUDY2023-1359 briefTitle: Targeting Chronic Stress for Reducing Risk Factors for Colorectal Cancer acronym: MindCRC overallStatus: NOT_YET_RECRUITING date: 2024-04-22 date: 2025-04-15 date: 2025-08-31 date: 2024-03-21 date: 2024-03-21 name: University of Illinois at Chicago class: OTHER briefSummary: Many neighborhoods in Chicago experience daily exposure to stressors including economic inopportunity and violent crime in public spaces. There is mounting evidence that chronic psychosocial stress can facilitate carcinogenesis by modulating the gut microbiome and immune system. The proposed research aims to study the practice of mindfulness to mitigate CPS and reduce colorectal cancer risk factors among Black American women at elevated risk. conditions: Mindfulness conditions: Colon Cancer conditions: Females studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 40 type: ESTIMATED name: Mindfulness measure: Feasibility measures measure: Acceptability measure: Body mass index measure: Stress measure measure: Fasting glucose measure: Gut microbiota composition measure: Gut inflammation measure: Adiposity measure: Epinephrine measure: Norepinephrine measure: Cortisol measure: Resting heart rate measure: Blood lipids measure: Fasting insulin measure: Hemoglobin A1c measure: Systemic inflammation sex: FEMALE minimumAge: 45 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Illinois at Chicago city: Chicago state: Illinois zip: 60612 country: United States name: Lisa Tussing-Humphreys, PhD role: CONTACT phone: 312-355-5521 email: tussing@uic.edu lat: 41.85003 lon: -87.65005 hasResults: False
nctId: NCT06323408 id: BZKF-AYA_1.0 briefTitle: Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas acronym: BZKF-AYA overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-09 date: 2026-03 date: 2024-03-21 date: 2024-03-21 name: University Hospital Regensburg class: OTHER briefSummary: The treatment of adolescents and young adults (AYA, 15 to 39 years) with malignant intra-axial CNS parenchymal tumors such as IDH-mutated gliomas, medulloblastomas and ependymomas is still not curative in all cases. The tumor biology and clinical needs to diagnose and treat these tumors are comparable across all age groups, so an integrated treatment environment overseen by adult and pediatric neuro-oncology specialists seems promising to leverage synergisms and advance diagnostic and therapeutic development in these tumors. A comprehensive, prospective and integrated biomaterial and imaging-based pipeline for the multi-faceted evaluation of AYAs has not yet been established for AYA patients with brain tumors in Germany. Current diagnostic platforms neglect the integrative processing of data from MRI and FET-PET imaging, radiotherapy plans, tumor tissue, liquid biopsies and clinical data as well as prognostic markers. A prospective AYA pipeline can therefore enable a better understanding of the aforementioned high-risk CNS malignancies and promises clinical advances for AYA patients and the clinical and scientific research landscape. conditions: Glioma, Malignant conditions: Embryonal Tumor conditions: Medulloblastoma conditions: Ependymoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 72 type: ESTIMATED name: Tissue, blood, cerebrospinal-spinal fluid measure: AI processing of MRI fand PET or diagnosis measure: AI processing of MRI and PET for evaluation of response and relapse measure: Quality control analysis in radiotherapy measure: Analysis of response in liquid biopsies measure: Target molecules in tissue and liquid biopsies measure: Evaluation of progression free survival sex: ALL minimumAge: 15 Years maximumAge: 39 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06323395 id: JGL-DED-VIZ-SLB 21 briefTitle: Vizol S Lipid Balance Efficacy and Safety Study in Patients With Dry Eye overallStatus: COMPLETED date: 2022-06-01 date: 2022-12-01 date: 2022-12-01 date: 2024-03-21 date: 2024-03-21 name: Jadran Galenski laboratorij d.d. class: INDUSTRY name: Poseidon CRO briefSummary: The clinical investigation was intended to investigate the efficacy, ocular tolerability and safety of Vizol S Lipid Balance, a new eye drops, emulsion developed by JADRAN - GALENSKI LABORATORIJ d.d., in patients with moderate to severe evaporative DED after a treatment for 30 days. conditions: Dry Eye Disease studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Multi-centre, randomised, parallel-group, controlled (placebo), double-blind study primaryPurpose: SUPPORTIVE_CARE masking: TRIPLE maskingDescription: As the clinical trial will be conducted in a double-blind way, both investigators and patients will be blind with respect to the treatment administered. For the purpose of individual unblinding of a patient's treatment the investigator will receive a sealed emergency envelope for each patient containing the treatment code (Only in case of medical emergency it is permitted to open the emergency envelope). whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 64 type: ACTUAL name: Vizol S LIPID BALANCE eye drops name: ophthalmic saline eye drops measure: Mean change in the tear film break-up time (TFBUT) from Visit 1 (baseline) to Visit 3 (day 30) measure: Mean change in the tear film break-up time (TFBUT) from Visit 1 (baseline) to Visit 2 (day 15) measure: percent (%) change in the tear film break-up time (TFBUT) from Visit 1 (baseline) to Visit 2 (day 15) and from Visit 1 (baseline) to Visit 3 (day 30) measure: Mean change in ocular surface staining score (total corneal and total conjunctival staining score) from Visit 1 (baseline) to Visit 3 (day 30) measure: Mean change in OSDI score from Visit 1 (baseline) to Visit 3 (day 30) measure: Mean change in Meibomian gland expression from Visit 1 (baseline) to Visit 3 (day 30) measure: The presence of Adverse Event/ /Serious Adverse Event (AE/ /SAE) throughout the investigation period measure: BCVA measure: Frequency of ocular signs sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Special eye hospital - Beogradski oftalmološki centar city: Belgrad zip: 11000 country: Serbia lat: 44.80401 lon: 20.46513 facility: Specialized clinic for eye desease - klinika Veselinović city: Niš zip: 18000 country: Serbia lat: 43.32472 lon: 21.90333 hasResults: False
nctId: NCT06323382 id: Liver Project 6 briefTitle: Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma overallStatus: RECRUITING date: 2021-01-01 date: 2024-12-30 date: 2024-12-30 date: 2024-03-21 date: 2024-03-21 name: Sun Yat-sen University class: OTHER briefSummary: Atezolizumab + Bevacizumab was superior to sorafenib in overall survival in advanced hepatocellular carcinoma. The programmed cell death protein-1 (PD1) and PDL1 inhibitor, was effective and tolerable in patients with advanced hepatocellular carcinoma. We aimed to describe the efficacy and safety of locoregional therapy combined with Bevacizumab and PD1/L1 inhibitor in patients with advanced hepatocellular carcinoma who can not receive radical therapy. conditions: Advanced Hepatocellular Carcinoma conditions: Anti-PD1/PDL1 Antibody conditions: Bevacizumab studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 240 type: ESTIMATED name: Locoregional therapy name: Bevacizumab name: Atezolizumab name: Tislelizumab name: Toripalimab name: Sintilimab name: Camrelizumab measure: Progression-Free-Survival (PFS) measure: Overall survival (OS) measure: Objective response rate (ORR) measure: Adverse events sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chinese PLA hospital status: RECRUITING city: Beijing state: Beijing zip: 100853 country: China name: Qunfang Zhou, Md role: CONTACT phone: 8619868000115 email: zhouqun988509@163.com name: MD role: CONTACT phone: 8613910984586 email: duanfeng@vip.sina.com name: Feng Duan, MD role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06323369 id: SYSKY-2023-1283-02 briefTitle: Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma overallStatus: RECRUITING date: 2024-03-25 date: 2029-03-25 date: 2029-09-25 date: 2024-03-21 date: 2024-03-21 name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University class: OTHER briefSummary: A prospective, randomized, open-label, multicenter Phase 2 trial designed to compare the efficacy and safety of Tislelizumab combined with chemotherapy followed by surgery versus up-front surgery in resectable clinically node-negative head and neck squamous cell carcinoma. conditions: Head and Neck Squamous Cell Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 154 type: ESTIMATED name: Tislelizumab（neoadjuvant） name: Cisplatin （neoadjuvant） name: Nab-paclitaxel （neoadjuvant） name: Surgical resection name: Cisplatin（adjuvant） name: Tislelizumab（adjuvant） name: Radiation name: Carboplatin（neoadjuvant） name: Carboplatin（adjuvant） measure: Disease-Free Survival(DFS ) measure: Lymph node positivity rate measure: Percentage of Participants Who Experienced High-Grade (Grade 3-4 and Grade 5) Adverse Events measure: Pathological complete response (pCR) rate measure: Major Pathological Response (MPR) rate measure: lymph node division measure: Event-free Survival (EFS) measure: Overall survival (OS) measure: Disease-Free Survival(DFS ) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Medical Ethics Committee of Sun Yat-sen Memorial Hospital status: RECRUITING city: Guangzhou state: Yuexiu zip: 510120 country: China name: Song Fan, Doctor role: CONTACT phone: 13570536658 phoneExt: +86 email: fansong2@mail.sysu.edu.cn name: Song Fan, Doctor role: PRINCIPAL_INVESTIGATOR lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06323356 id: TAK-279-PsO-3005 id: jRCT2031230714 type: REGISTRY domain: jRCT briefTitle: A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis overallStatus: RECRUITING date: 2024-03-19 date: 2025-06-30 date: 2026-03-27 date: 2024-03-21 date: 2024-04-10 name: Takeda class: INDUSTRY briefSummary: The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279.
nctId: NCT06323343 id: 00040976 briefTitle: Mobile Video Education to Improve Patient Clinician Communication During Prenatal Clinic Visits overallStatus: NOT_YET_RECRUITING date: 2024-05-28 date: 2024-10-01 date: 2025-01-31 date: 2024-03-21 date: 2024-03-21 name: Medical College of Wisconsin class: OTHER briefSummary: The goal of this clinical trial is to test an animated video delivered by text message in patients whose pregnancies are complicated with fetal anomalies. The main question it aims to answer is: Does the video intervention prepare parents to talk to the doctors during prenatal appointments?
The researchers will compare the video and webpage groups to see which group reports engaging in more of the identified best-practices of communication. conditions: Patient Empowerment studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: DOUBLE whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 114 type: ESTIMATED name: Video Intervention name: Webpage links measure: Parents' communication behaviors measure sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06323330 id: I-1623 briefTitle: Music Therapy for Rehabilitation in Post-stroke Non-fluent Aphasia: the Indian Adaptation overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-10-31 date: 2026-11-30 date: 2024-03-21 date: 2024-03-21 name: All India Institute of Medical Sciences, New Delhi class: OTHER name: Institute of Human Behavior and Allied Sciences name: Indian Institute of Technology, New Delhi name: Vardhman Mahavir Medical College And Safdarjung Hospital briefSummary: The goal of this Interventional Study is to develop and test the Indian Adaptation of Melodic Intonation Therapy (MIT) for Indian patients in with post-stroke Non-Fluent Aphasia (PSNFA). The main question\[s\] it aims to answer are: • To develop the MIT Indian Adaptation tool and check its feasibility • To compare the MIT with standard speech rehabilitation in patient with PSNFA. Participants will undergo Speech Rehabilitation according to the developed module and the standard treatment will be given in the comparator arm. The speech recovery at 12 weeks will be compared in both treatment arms. conditions: Stroke Rehabilitation conditions: Aphasia, Broca studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The MIT- Indian Adaptation will be tested and compared with standard speech rehabilitation in post-stroke non-fluent aphasia primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The outcome assessor will be blinded to the intervention whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Speech rehabilitation measure: Western Aphasia Battery Score measure: Western Aphasia Battery Score measure: functional Near Red Spectroscopy measures measure: modified Rankin Score measure: Fugl Meyer Assessment Scores sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06323317 id: UW 21-405 briefTitle: A Prehabilitation Program for Frail Patients Undergoing Cardiac Surgeries/Procedures acronym: PREHAB overallStatus: RECRUITING date: 2023-12-18 date: 2024-12-31 date: 2025-03-31 date: 2024-03-21 date: 2024-03-21 name: The University of Hong Kong class: OTHER briefSummary: The purpose of this study is to develop and evaluate a frailty-specific prehabilitation program for patients awaiting cardiac surgeries/procedures. The program aims to improve functional capacity, frailty level, cardiac-related physical functioning, health-related quality of life (HRQoL), psychological distress, major adverse cardiovascular and cerebral events (MACCE), hospital length of stay, and readmission rates.
Prehabilitation, which optimizes patients' physiological and functional capacities before surgery, has shown promise in general cardiac patients but requires a more comprehensive approach for frail individuals. This randomized controlled trial will recruit 50 Chinese adults awaiting elective cardiac surgeries/procedures in Hong Kong. Participants will be randomly assigned to either the intervention group, receiving a comprehensive prehabilitation program, or the control group, receiving routine preoperative care. Assessments will be conducted at baseline and at three postoperative time points.
The findings will contribute to our understanding of the impact of frailty on postoperative outcomes and help develop strategies to improve patient care. Ultimately, this study aims to reduce healthcare burdens associated with cardiac disease-related morbidity and disability. conditions: Coronary Artery Bypass Grafting conditions: Heart Valve Replacement conditions: Transcatheter Aortic Valve Implantation conditions: Frailty studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE maskingDescription: The post-intervention data collector (research assistant) will be blinded to the group allocation to avoid performance and detection biases. whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: Multi-component exercise programme name: Attention Placebo name: Structured preoperative education name: Nutritional optimization name: Stress management measure: The Short Physical Performance Battery (SPPB) measure: Weakness/ Grip Strength (Fried Phenotype Frailty Assessment) measure: Slowness (Fried Phenotype Frailty Assessment) measure: Low Physical Activity (Fried Phenotype Frailty Assessment) measure: Self-reported Exhaustion (Fried Phenotype Frailty Assessment) measure: Unintentional Weight Loss (Fried Phenotype Frailty Assessment) measure: The Seattle Angina Questionnaire (SAQ) measure: The MacNew Heart Disease Health-Related Quality of Life Questionnaire measure: The Hospital Anxiety and Depression Scale (HADS) measure: Biomarkers-Serum albumin measure: Biomarkers- C-reactive protein measure: Major adverse cardiac and cerebrovascular events (MACCE) measure: Hospital Length of stay measure: Hospital Readmissions sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Polly Wai Chi status: RECRUITING city: Hong Kong state: Please Select zip: 00000 country: Hong Kong name: Polly Wai Chi Li, PhD role: CONTACT email: pwcli@hku.hk lat: 22.27832 lon: 114.17469 hasResults: False